SI1929297T1 - Bioloĺ ki oznaäśevalci pri multipli sklerozi in metode za njihovo uporabo - Google Patents

Bioloĺ ki oznaäśevalci pri multipli sklerozi in metode za njihovo uporabo

Info

Publication number
SI1929297T1
SI1929297T1 SI200631526T SI200631526T SI1929297T1 SI 1929297 T1 SI1929297 T1 SI 1929297T1 SI 200631526 T SI200631526 T SI 200631526T SI 200631526 T SI200631526 T SI 200631526T SI 1929297 T1 SI1929297 T1 SI 1929297T1
Authority
SI
Slovenia
Prior art keywords
biomarkers
methods
multiple sclerosis
sclerosis
Prior art date
Application number
SI200631526T
Other languages
English (en)
Inventor
Aaron B. Kantor
Susan Goelz
Jun Deng
Hua Lin
Christopher Becker
Original Assignee
Caprion Proteomics Usa, Llc
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caprion Proteomics Usa, Llc, Biogen Idec Ma Inc. filed Critical Caprion Proteomics Usa, Llc
Publication of SI1929297T1 publication Critical patent/SI1929297T1/sl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200631526T 2005-09-29 2006-09-29 Bioloĺ ki oznaäśevalci pri multipli sklerozi in metode za njihovo uporabo SI1929297T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72217205P 2005-09-29 2005-09-29
EP06815711A EP1929297B1 (en) 2005-09-29 2006-09-29 Biomarkers for multiple sclerosis and methods of use thereof
PCT/US2006/037924 WO2007041245A2 (en) 2005-09-29 2006-09-29 Biomarkers for multiple sclerosis and methods of use thereof

Publications (1)

Publication Number Publication Date
SI1929297T1 true SI1929297T1 (sl) 2013-06-28

Family

ID=37906719

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631526T SI1929297T1 (sl) 2005-09-29 2006-09-29 Bioloĺ ki oznaäśevalci pri multipli sklerozi in metode za njihovo uporabo

Country Status (5)

Country Link
US (2) US20100062471A1 (sl)
EP (2) EP1929297B1 (sl)
DK (1) DK1929297T3 (sl)
SI (1) SI1929297T1 (sl)
WO (1) WO2007041245A2 (sl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
WO2005112970A2 (en) 2004-05-12 2005-12-01 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat infections
PL3279663T3 (pl) 2006-03-15 2022-01-10 The Brigham And Women's Hospital, Inc. Zastosowanie gelsoliny do diagnozowania i leczenia chorób zapalnych
US8440622B2 (en) * 2006-03-15 2013-05-14 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel)
CA2662639C (en) * 2006-09-18 2013-06-04 Multiple Sclerosis Research Center Of New York Fetuin-a as a biomarker for multiple sclerosis
EP1988175A1 (en) * 2007-05-03 2008-11-05 Bayer Schering Pharma Aktiengesellschaft Predictive RNA profiles
DE102007041657A1 (de) * 2007-09-03 2009-03-05 Protagen Ag Markersequenzen für Multiple Sklerose und deren Verwendung
DK2250280T3 (en) 2008-01-25 2015-03-09 Gen Hospital Corp THERAPEUTIC USES OF gelsolin in renal failure
EP2347352B1 (en) * 2008-09-16 2019-11-06 Beckman Coulter, Inc. Interactive tree plot for flow cytometry data
WO2017120461A1 (en) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
NZ609938A (en) * 2010-10-11 2015-11-27 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
EP3421487B1 (en) 2010-10-19 2023-06-28 The Regents of the University of Colorado, a body corporate Peptides for modulating t-cell activity and uses thereof
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
US8945935B2 (en) 2011-08-04 2015-02-03 Technion Research & Development Foundation Ltd. Diagnosing, prognosing and monitoring multiple sclerosis
WO2014143977A2 (en) * 2013-03-15 2014-09-18 Sera Prognostics, Inc. Biomarkers and methods for predicting preeclampsia
US20160040236A1 (en) * 2013-03-15 2016-02-11 Biogen Ma Inc. Systems and methods for characterization of multiple sclerosis
US20150331946A1 (en) * 2013-07-25 2015-11-19 Theranos, Inc. Systems and methods for a distributed clinical laboratory
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
BR112016012968A2 (pt) 2013-12-09 2017-08-08 Univ Leland Stanford Junior Métodos e composições para o tratamento de condições associadas com o envelhecimento
US20170108514A1 (en) * 2014-03-23 2017-04-20 The Regents Of The University Of Colorado, A Body Corporate Diagnosis of multiple sclerosis in human and animal subjects
WO2016040861A1 (en) * 2014-09-12 2016-03-17 Biogen Ma Inc. Systems and methods for characterization of multiple sclerosis
KR20210041137A (ko) 2015-06-15 2021-04-14 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 노화와 연관된 질환을 치료하기 위한 방법 및 조성물
IL256399B (en) 2015-06-19 2022-09-01 Sera Prognostics Inc Pairs of biomarkers for predicting premature birth
WO2017053838A1 (en) * 2015-09-23 2017-03-30 Oklahoma Medical Research Foundation Biomarkers for assessing subjects with multiple sclerosis
WO2017058999A2 (en) * 2015-09-29 2017-04-06 Crescendo Bioscience Biomarkers and methods for assessing response to inflammatory disease therapy withdrawal
AU2017286979B2 (en) * 2016-07-01 2023-04-27 Dignity Health Diagnostic or predictor of relapsing remitting multiple sclerosis
EP3668996A4 (en) 2017-08-18 2021-04-21 Sera Prognostics, Inc. CLOCK PREGNANCY PROTEIN FOR PREDICTING THE DATE AND TIME TO BIRTH
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
WO2022051674A1 (en) * 2020-09-04 2022-03-10 Octave Bioscience, Inc. Biomarkers for predicting multiple sclerosis disease progression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432662B1 (en) 1997-04-15 2002-08-13 Pierce Chemical Company Assay of peroxidase activity
US6753135B2 (en) * 2000-09-20 2004-06-22 Surromed, Inc. Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
US6835927B2 (en) 2001-10-15 2004-12-28 Surromed, Inc. Mass spectrometric quantification of chemical mixture components
WO2004015420A1 (en) * 2002-08-02 2004-02-19 Glycominds Ltd. Method for diagnosing multiple sclerosis

Also Published As

Publication number Publication date
US20100062471A1 (en) 2010-03-11
EP2517727A2 (en) 2012-10-31
EP1929297B1 (en) 2012-11-21
EP1929297A2 (en) 2008-06-11
EP1929297A4 (en) 2010-02-24
US20150031562A1 (en) 2015-01-29
WO2007041245A3 (en) 2009-05-07
EP2517727A3 (en) 2013-10-30
WO2007041245A2 (en) 2007-04-12
DK1929297T3 (da) 2013-03-04

Similar Documents

Publication Publication Date Title
SI1929297T1 (sl) Bioloĺ ki oznaäśevalci pri multipli sklerozi in metode za njihovo uporabo
ZA200802501B (en) Indenoisoquinolinone analogs and methods of use thereof
IL176958A0 (en) Compounds and methods of use
ZA200802822B (en) Raf inhibitor compounds and methods of use thereof
ZA200710969B (en) Raf inhibitor compounds and methods of use thereof
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
EP2023718A4 (en) CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR
IL188078A0 (en) Nano-ionic liquids and methods of use
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
IL187303A0 (en) Methods of prepering 3 - cyano - quinolines and intermediates made thereby
EP1931205A4 (en) TRANSGLUTAMINASE INHIBITORS AND METHOD OF USE THEREOF
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
IL194028A0 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
IL190226A0 (en) Organometallic compounds and methods of use thereof
EP1812451A4 (en) COMPOUNDS AND METHODS OF USE THEREOF
HK1161122A1 (en) Use of 24-norudca 24-norudca
GB0502979D0 (en) Biomarkers and uses thereof
EP2069521A4 (en) BIOMARKERS OF SCLEROSIS IN PLATE
EP1951894A4 (en) MICROARRAYSES FOR GENOTYPING AND METHODS OF USE
GB0520930D0 (en) Composition and method of use
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
EP1978999A4 (en) ISOLATED MCPIP PROTEIN AND METHODS OF USE
ZA200901009B (en) Aza-benzothiophenyl compounds and methods of use
EP1933820A4 (en) PALMARUMYCIN BASED INHIBITORS OF THIOREDOXIN AND METHOD OF ADMINISTRATION